Combined Treatment of Adipose Derived-Mesenchymal Stem Cells and Pregabalin Is Superior to Monotherapy for the Treatment of Neuropathic Pain in Rats

Abstract

Aims. Neuropathic pain following nerve injury does not respond well to most available pharmacological remedies. We aimed to compare the outcome of the addition of adipose-derived mesenchymal stem cells (ADMSCs) to pregabalin for neuropathic pain treatment. Methods. Adult female albino rats ( n = 100 ) were randomized to receive traumatic sciatic nerve injury or sham. Animals were then randomized to ADMSC treatment with or without pregabalin. We conducted a battery of neurobehavioral and electrophysiological to assess neuropathic pain. Following sacrifice, we evaluated the histological changes and gene expression of brain-derived neurotrophic factor (BDNF) in the sciatic nerve. Serum and sciatic nerve tissue pro- and inflammatory cytokine levels were also assessed. Results. (1) All treatments significantly improved thermal withdrawal latency, sciatic nerve conduction velocity, and proinflammatory cytokine levels in injured animals, with no significant effect of the combined treatments compared to pregabalin monotherapy ( p < 0.05 each). (2) Combined treatment significantly improved medial gastrocnemius electromyographic amplitude and sciatic function index compared to pregabalin monotherapy ( p < 0.05 each). (3) Combined treatment significantly increased the BDNF expression, decreased anti-inflammatory cytokine ( p < 0.05 each), and restored the structural nerve damage, compared to pregabalin monotherapy. Conclusions. Combined treatment is associated with greater improvement of the sciatic nerve structure and function. Further studies are warranted to study the mechanism of action of the combined treatment to improve neuropathic pain.

Why Use Adipose-Derived Mesenchymal Stem Cells in Tendinopathic Patients: A Systematic Review

“…This was evident not only in the improvement of the VAS score but also by MRI or US evaluations. In this regard, tendon pain recovery induced by ASCs was in line with previous evidence, reporting a rapid and long-lasting pain relief after the application of ASCs in pre-clinical and clinical osteoarthritis, musculoskeletal and neuropathic pain [63][64][65][66]. From the mechanistic point of view, it may be that the therapeutic efficacy of ASCs in tendon pain could be due to ASCs paracrine anti-inflammatory and anti-oxidative activities [67].…”

Co-Administration of Resolvin D1 and Peripheral Nerve-Derived Stem Cell Spheroids as a Therapeutic Strategy in a Rat Model of Spinal Cord Injury

“…Within the realm of SCI, neuroprotective agents are commonly used in clinical settings. These agents can be broadly categorized into calcium antagonists, glutamate release inhibitors, neurotrophic factors, free radical scavengers, cell membrane stabilizers, anti-inflammatory factors, glutamate antagonists, excitatory amino acid antagonists, gamma-aminobutyric acid receptor agonists, and leukocyte adhesion inhibition agents, based on their respective mechanisms of action [ 9 , 79 , 80 ]. Unfortunately, most of these pharmaceuticals are either ineffective or cause adverse effects.…”

Diagnosis and Management of Neuropathic Pain in Spine Diseases

“…SCT can potentially alleviate neuropathic pain through anti-inflammatory action, the suppression of central sensitization and the inhibition of glial cell activation [ 200 ]. In numerous studies on animal models, the potential effectiveness of SCT for neuropathic pain has been proven [ 227 , 228 , 229 ]. A clinical trial by Vaquero et al demonstrated that therapy with intrathecally administered mesenchymal stromal cells (MSCs) significantly and progressively decreased neuropathic pain in patients after spinal cord injury ( p < 0.003) [ 199 ].…”